Cargando…

Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement

INTRODUCTION: Urokinase-type plasminogen activator (u-PA) has been implicated in fibrinolysis, cell migration, latent cytokine activation, cell activation, T-cell activation, and tissue remodeling, all of which are involved in the development of rheumatoid arthritis. Previously, u-PA has been report...

Descripción completa

Detalles Bibliográficos
Autores principales: Cook, Andrew D, De Nardo, Christine M, Braine, Emma L, Turner, Amanda L, Vlahos, Ross, Way, Kerrie J, Beckman, S Kaye, Lenzo, Jason C, Hamilton, John A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888184/
https://www.ncbi.nlm.nih.gov/pubmed/20196869
http://dx.doi.org/10.1186/ar2946
_version_ 1782182631587184640
author Cook, Andrew D
De Nardo, Christine M
Braine, Emma L
Turner, Amanda L
Vlahos, Ross
Way, Kerrie J
Beckman, S Kaye
Lenzo, Jason C
Hamilton, John A
author_facet Cook, Andrew D
De Nardo, Christine M
Braine, Emma L
Turner, Amanda L
Vlahos, Ross
Way, Kerrie J
Beckman, S Kaye
Lenzo, Jason C
Hamilton, John A
author_sort Cook, Andrew D
collection PubMed
description INTRODUCTION: Urokinase-type plasminogen activator (u-PA) has been implicated in fibrinolysis, cell migration, latent cytokine activation, cell activation, T-cell activation, and tissue remodeling, all of which are involved in the development of rheumatoid arthritis. Previously, u-PA has been reported to play a protective role in monoarticular arthritis models involving mBSA as the antigen, but a deleterious role in the systemic polyarticular collagen-induced arthritis (CIA) model. The aim of the current study is to determine how u-PA might be acting in systemic arthritis models. METHODS: The CIA model and bone marrow chimeras were used to determine the cellular source of u-PA required for the arthritis development. Gene expression of inflammatory and destructive mediators was measured in joint tissue by quantitiative PCR and protein levels by ELISA. The requirement for u-PA in the type II collagen mAb-induced arthritis (CAIA) and K/BxN serum transfer arthritis models was determined using u-PA(-/- )mice. Neutrophilia was induced in the peritoneal cavity using either ovalbumin/anti-ovalbumin or the complement component C5a. RESULTS: u-PA from a bone marrow-derived cell was required for the full development of CIA. The disease in u-PA(-/- )mice reconstituted with bone marrrow from C57BL/6 mice was indistinguishable from that in C57BL/6 mice, in terms of clincal score, histologic features, and protein and gene expression of key mediators. u-PA(-/- )mice were resistant to both CAIA and K/BxN serum transfer arthritis development. u-PA(-/- )mice developed a reduced neutrophilia and chemokine production in the peritoneal cavity following ovalbumin/anti-ovalbumin injection; in contrast, the peritoneal neutrophilia in response to C5a was u-PA independent. CONCLUSIONS: u-PA is required for the full development of systemic arthritis models involving immune complex formation and deposition. The cellular source of u-PA required for CIA is bone marrow derived and likely to be of myeloid origin. For immune complex-mediated peritonitis, and perhaps some other inflammatory responses, it is suggested that the u-PA involvement may be upstream of C5a signaling.
format Text
id pubmed-2888184
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28881842010-06-21 Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement Cook, Andrew D De Nardo, Christine M Braine, Emma L Turner, Amanda L Vlahos, Ross Way, Kerrie J Beckman, S Kaye Lenzo, Jason C Hamilton, John A Arthritis Res Ther Research article INTRODUCTION: Urokinase-type plasminogen activator (u-PA) has been implicated in fibrinolysis, cell migration, latent cytokine activation, cell activation, T-cell activation, and tissue remodeling, all of which are involved in the development of rheumatoid arthritis. Previously, u-PA has been reported to play a protective role in monoarticular arthritis models involving mBSA as the antigen, but a deleterious role in the systemic polyarticular collagen-induced arthritis (CIA) model. The aim of the current study is to determine how u-PA might be acting in systemic arthritis models. METHODS: The CIA model and bone marrow chimeras were used to determine the cellular source of u-PA required for the arthritis development. Gene expression of inflammatory and destructive mediators was measured in joint tissue by quantitiative PCR and protein levels by ELISA. The requirement for u-PA in the type II collagen mAb-induced arthritis (CAIA) and K/BxN serum transfer arthritis models was determined using u-PA(-/- )mice. Neutrophilia was induced in the peritoneal cavity using either ovalbumin/anti-ovalbumin or the complement component C5a. RESULTS: u-PA from a bone marrow-derived cell was required for the full development of CIA. The disease in u-PA(-/- )mice reconstituted with bone marrrow from C57BL/6 mice was indistinguishable from that in C57BL/6 mice, in terms of clincal score, histologic features, and protein and gene expression of key mediators. u-PA(-/- )mice were resistant to both CAIA and K/BxN serum transfer arthritis development. u-PA(-/- )mice developed a reduced neutrophilia and chemokine production in the peritoneal cavity following ovalbumin/anti-ovalbumin injection; in contrast, the peritoneal neutrophilia in response to C5a was u-PA independent. CONCLUSIONS: u-PA is required for the full development of systemic arthritis models involving immune complex formation and deposition. The cellular source of u-PA required for CIA is bone marrow derived and likely to be of myeloid origin. For immune complex-mediated peritonitis, and perhaps some other inflammatory responses, it is suggested that the u-PA involvement may be upstream of C5a signaling. BioMed Central 2010 2010-03-02 /pmc/articles/PMC2888184/ /pubmed/20196869 http://dx.doi.org/10.1186/ar2946 Text en Copyright ©2010 Cook et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research article
Cook, Andrew D
De Nardo, Christine M
Braine, Emma L
Turner, Amanda L
Vlahos, Ross
Way, Kerrie J
Beckman, S Kaye
Lenzo, Jason C
Hamilton, John A
Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement
title Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement
title_full Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement
title_fullStr Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement
title_full_unstemmed Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement
title_short Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement
title_sort urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement
topic Research article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888184/
https://www.ncbi.nlm.nih.gov/pubmed/20196869
http://dx.doi.org/10.1186/ar2946
work_keys_str_mv AT cookandrewd urokinasetypeplasminogenactivatorandarthritisprogressionroleinsystemicdiseasewithimmunecomplexinvolvement
AT denardochristinem urokinasetypeplasminogenactivatorandarthritisprogressionroleinsystemicdiseasewithimmunecomplexinvolvement
AT braineemmal urokinasetypeplasminogenactivatorandarthritisprogressionroleinsystemicdiseasewithimmunecomplexinvolvement
AT turneramandal urokinasetypeplasminogenactivatorandarthritisprogressionroleinsystemicdiseasewithimmunecomplexinvolvement
AT vlahosross urokinasetypeplasminogenactivatorandarthritisprogressionroleinsystemicdiseasewithimmunecomplexinvolvement
AT waykerriej urokinasetypeplasminogenactivatorandarthritisprogressionroleinsystemicdiseasewithimmunecomplexinvolvement
AT beckmanskaye urokinasetypeplasminogenactivatorandarthritisprogressionroleinsystemicdiseasewithimmunecomplexinvolvement
AT lenzojasonc urokinasetypeplasminogenactivatorandarthritisprogressionroleinsystemicdiseasewithimmunecomplexinvolvement
AT hamiltonjohna urokinasetypeplasminogenactivatorandarthritisprogressionroleinsystemicdiseasewithimmunecomplexinvolvement